{"id":746069,"date":"2019-03-05T18:37:00","date_gmt":"2019-03-05T18:37:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-prices-5-0-billion-debt-offering\/"},"modified":"2025-05-12T08:58:17","modified_gmt":"2025-05-12T12:58:17","slug":"merck-prices-5-0-billion-debt-offering","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-prices-5-0-billion-debt-offering\/","title":{"rendered":"Merck Prices $5.0 Billion Debt Offering"},"content":{"rendered":"<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today priced a $5.0 billion public offering of four series of senior<br \/>\n      unsecured notes (collectively, the \u201cNotes\u201d). The Notes include:\n    <\/p>\n<p class=\"bwalignc\">\n      $750 million of 2.90% notes due 2024\n    <\/p>\n<p class=\"bwalignc\">\n      $1,750 million of 3.40% notes due 2029\n    <\/p>\n<p class=\"bwalignc\">\n      $1,000 million of 3.90% notes due 2039\n    <\/p>\n<p class=\"bwalignc\">\n      $1,500 million of 4.00% notes due 2049\n    <\/p>\n<p>\n      Merck intends to use the net proceeds from the offering for general<br \/>\n      corporate purposes, including without limitation the repayment of<br \/>\n      outstanding commercial paper borrowings and other indebtedness with<br \/>\n      upcoming maturities. The offering is expected to close on March 7, 2019,<br \/>\n      subject to customary closing conditions. Goldman Sachs &amp; Co. LLC, J.P.<br \/>\n      Morgan Securities LLC and Morgan Stanley &amp; Co. LLC are acting as the<br \/>\n      active joint book-running managers for the offering.\n    <\/p>\n<p>\n      The offering of the Notes is being made pursuant to an effective shelf<br \/>\n      registration statement (including a base prospectus) filed with the<br \/>\n      Securities and Exchange Commission (the \u201cSEC\u201d). The offering may be made<br \/>\n      only by means of a prospectus and related prospectus supplement, copies<br \/>\n      of which may be obtained by calling Goldman Sachs &amp; Co. LLC at<br \/>\n      1-866-471-2526, J.P. Morgan Securities LLC at 1-212-834-4533 or Morgan<br \/>\n      Stanley &amp; Co. LLC at 1-866-718-1649. An electronic copy of the<br \/>\n      registration statement and prospectus supplement, together with the base<br \/>\n      prospectus, is available on the SEC\u2019s website at <a href=\"https:\/\/www.sec.gov\/\" rel=\"nofollow\">www.sec.gov<\/a>.\n    <\/p>\n<p>\n      This press release does not constitute an offer to sell or a<br \/>\n      solicitation of an offer to buy the securities described herein, nor<br \/>\n      shall there be any sale of these securities in any state or jurisdiction<br \/>\n      in which such an offer, solicitation or sale would be unlawful prior to<br \/>\n      registration or qualification under the securities laws of any such<br \/>\n      jurisdiction.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. Such statements may include, but are not limited to,<br \/>\n      the company\u2019s ability to complete the offering and the company\u2019s<br \/>\n      expectations for the use of proceeds from the offering. These statements<br \/>\n      are based upon the current beliefs and expectations of the company\u2019s<br \/>\n      management and are subject to significant risks and uncertainties. If<br \/>\n      underlying assumptions prove inaccurate or risks or uncertainties<br \/>\n      materialize, actual results may differ materially from those set forth<br \/>\n      in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2018 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"https:\/\/www.sec.gov\/\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p>\n<img decoding=\"async\" alt=\"\" src=\"https:\/\/www.businesswire.com\/images\/spacer.gif\" style=\"width:0;height:0\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Media Contacts:     <\/p>\n<p>       Pamela Eisele<br \/>(267) 305-3558     <\/p>\n<p>       Jennifer Mauer<br \/>(908) 740-1801     <\/p>\n<p>       Investor Contacts:     <\/p>\n<p>       Peter Dannenbaum<br \/>(908) 740-1037     <\/p>\n<p>       Courtney Ronaldo<br \/>(908) 740-6132     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today priced a $5.0 billion public offering of four series of senior unsecured notes (collectively, the \u201cNotes\u201d). The Notes include: $750 million of 2.90% notes due 2024 $1,750 million of 3.40% notes due 2029 $1,000 million of 3.90% notes due 2039 $1,500 million of 4.00% notes due 2049 Merck intends to use the net proceeds from the offering for general corporate purposes, including without limitation the repayment of outstanding commercial paper borrowings and other indebtedness with upcoming maturities. The offering is expected to close on March 7, 2019, subject to customary closing conditions. Goldman Sachs &amp; Co. LLC, J.P. Morgan Securities LLC and Morgan Stanley &amp; Co. LLC are acting as the active joint book-running managers for the offering. The offering of the Notes is being made pursuant to an effective shelf registration statement (including a base prospectus) filed with the Securities and Exchange<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-746069","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Prices $5.0 Billion Debt Offering - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-prices-5-0-billion-debt-offering\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Prices $5.0 Billion Debt Offering - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today priced a $5.0 billion public offering of four series of senior unsecured notes (collectively, the \u201cNotes\u201d). The Notes include: $750 million of 2.90% notes due 2024 $1,750 million of 3.40% notes due 2029 $1,000 million of 3.90% notes due 2039 $1,500 million of 4.00% notes due 2049 Merck intends to use the net proceeds from the offering for general corporate purposes, including without limitation the repayment of outstanding commercial paper borrowings and other indebtedness with upcoming maturities. The offering is expected to close on March 7, 2019, subject to customary closing conditions. Goldman Sachs &amp; Co. LLC, J.P. Morgan Securities LLC and Morgan Stanley &amp; Co. LLC are acting as the active joint book-running managers for the offering. The offering of the Notes is being made pursuant to an effective shelf registration statement (including a base prospectus) filed with the Securities and Exchange\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-prices-5-0-billion-debt-offering\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-12T12:58:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.businesswire.com\/images\/spacer.gif\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-prices-5-0-billion-debt-offering\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-prices-5-0-billion-debt-offering\\\/\",\"name\":\"Merck Prices $5.0 Billion Debt Offering - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-prices-5-0-billion-debt-offering\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-prices-5-0-billion-debt-offering\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\",\"datePublished\":\"2019-03-05T18:37:00+00:00\",\"dateModified\":\"2025-05-12T12:58:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-prices-5-0-billion-debt-offering\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-prices-5-0-billion-debt-offering\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-prices-5-0-billion-debt-offering\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\",\"contentUrl\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-prices-5-0-billion-debt-offering\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Prices $5.0 Billion Debt Offering\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Prices $5.0 Billion Debt Offering - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-prices-5-0-billion-debt-offering\/","og_locale":"en_US","og_type":"article","og_title":"Merck Prices $5.0 Billion Debt Offering - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today priced a $5.0 billion public offering of four series of senior unsecured notes (collectively, the \u201cNotes\u201d). The Notes include: $750 million of 2.90% notes due 2024 $1,750 million of 3.40% notes due 2029 $1,000 million of 3.90% notes due 2039 $1,500 million of 4.00% notes due 2049 Merck intends to use the net proceeds from the offering for general corporate purposes, including without limitation the repayment of outstanding commercial paper borrowings and other indebtedness with upcoming maturities. The offering is expected to close on March 7, 2019, subject to customary closing conditions. Goldman Sachs &amp; Co. LLC, J.P. Morgan Securities LLC and Morgan Stanley &amp; Co. LLC are acting as the active joint book-running managers for the offering. The offering of the Notes is being made pursuant to an effective shelf registration statement (including a base prospectus) filed with the Securities and Exchange","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-prices-5-0-billion-debt-offering\/","og_site_name":"Merck.com","article_modified_time":"2025-05-12T12:58:17+00:00","og_image":[{"url":"https:\/\/www.businesswire.com\/images\/spacer.gif","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-prices-5-0-billion-debt-offering\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-prices-5-0-billion-debt-offering\/","name":"Merck Prices $5.0 Billion Debt Offering - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-prices-5-0-billion-debt-offering\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-prices-5-0-billion-debt-offering\/#primaryimage"},"thumbnailUrl":"https:\/\/www.businesswire.com\/images\/spacer.gif","datePublished":"2019-03-05T18:37:00+00:00","dateModified":"2025-05-12T12:58:17+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-prices-5-0-billion-debt-offering\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-prices-5-0-billion-debt-offering\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-prices-5-0-billion-debt-offering\/#primaryimage","url":"https:\/\/www.businesswire.com\/images\/spacer.gif","contentUrl":"https:\/\/www.businesswire.com\/images\/spacer.gif"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-prices-5-0-billion-debt-offering\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Prices $5.0 Billion Debt Offering"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"34ce0742-c10e-4798-9cfe-6ce2cf2fa5cd","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Prices-50-Billion-Debt-Offering-2019.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/746069","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/746069\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=746069"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=746069"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}